GLP-1 Weight Loss Drugs Cut Grocery Spending 5 Percent, Oprah Shares Personal Experience cover art

GLP-1 Weight Loss Drugs Cut Grocery Spending 5 Percent, Oprah Shares Personal Experience

GLP-1 Weight Loss Drugs Cut Grocery Spending 5 Percent, Oprah Shares Personal Experience

Listen for free

View show details

About this listen

 Recent research from Cornell University reveals that weight-loss drugs like Ozempic and Wegovy are significantly reducing how much Americans spend on food. According to the study published in the Journal of Marketing Research, households cut grocery spending by an average of 5.3 percent within six months of starting these GLP-1 receptor agonist medications, with higher-income families seeing drops over 8 percent. Fast-food and coffee shop spending fell by about 8 percent too. The biggest declines hit savory snacks, sweets, baked goods, and cookies, down around 10 percent, while yogurt and fresh fruit purchases rose modestly. Sylvia Hristakeva, an assistant professor of marketing at Cornell, noted that these changes persist for at least a year among ongoing users but fade after stopping.

Oprah Winfrey shared her personal experiences with GLP-1 medications in recent interviews. Business Insider reports that the 71-year-old media icon regrets not discovering these drugs earlier, calling them a vital tool for managing obesity as a chronic disease. She described how the constant food noise in her head vanished within hours of her first dose, leaving her indifferent to food obsessions despite still enjoying it. Winfrey told CBS Sunday Morning she wept thinking of years wasted on shame, believing her struggles stemmed from personal failure rather than biology. After stopping for a year to test herself, she gained 20 pounds, proving to her that the medication is essential, much like blood pressure drugs.

On NBC's Today show, Winfrey discussed side effects from her GLP-1 use while promoting her new book with Yale's Dr. Ania M. Jastreboff. She experienced constipation but no nausea or diarrhea, managing it by drinking a gallon of water daily before 4 p.m. to keep her kidneys happy. The book aims to shift views on obesity, comparing stigma around these drugs to past misconceptions about alcoholism.

Experts predict further evolution for these treatments. Fox News Digital spoke with specialists forecasting 2026 shifts, including GLP-1s as multi-system metabolic modulators targeting heart, kidney, and liver health beyond just weight. Novo Nordisk launched a daily oral semaglutide pill nationwide on January 5, offering a convenient non-injection option. A new Oxford University study across 37 trials with over 9,000 adults found weight regain averages 0.4 kilograms per month after stopping these drugs.

Thanks for tuning in, listeners. Come back next week for more. Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.

Some great Deals https://amzn.to/49SJ3Qs

For more check out http://www.quietplease.ai

This content was created in partnership and with the help of Artificial Intelligence AI
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.